Aldosterone

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 240 Experts worldwide ranked by ideXlab platform

Roberto Pontremoli - One of the best experts on this subject based on the ideXlab platform.

Giuliano Tocci - One of the best experts on this subject based on the ideXlab platform.

Diego Alvarez De La Rosa - One of the best experts on this subject based on the ideXlab platform.

  • Regulation of Aldosterone Signaling by MicroRNAs.
    Vitamins and Hormones Series, 2018
    Co-Authors: Michael B. Butterworth, Diego Alvarez De La Rosa
    Abstract:

    Abstract The mineralocorticoid hormone Aldosterone is released by the adrenal glands in a homeostatic mechanism to regulate blood volume. Several cues elicit Aldosterone release, and the long-term action of the hormone is to restore blood pressure and/or increase the retrieval of sodium from filtered plasma in the kidney. While the signaling cascade that results in Aldosterone release is well studied, the impact of this hormone on tissues and cells in various organ systems is pleotropic. Emerging evidence indicates Aldosterone may alter non-coding RNAs (ncRNAs) to integrate the hormonal response, and these ncRNAs may contribute to the heterogeneity of signaling outcomes in Aldosterone target tissues. The best studied of the ncRNAs in Aldosterone action are the small ncRNAs, microRNAs. MicroRNA expression is regulated by Aldosterone stimulation, and microRNAs are able to modulate protein expression at all steps in the renin-angiotensin-Aldosterone-signaling system. The discovery and synthesis of microRNAs will be briefly covered followed by a discussion of the reciprocal role of Aldosterone/microRNA regulation, including misregulation of microRNA signaling in Aldosterone-linked disease states.

C Delcayre - One of the best experts on this subject based on the ideXlab platform.

  • Aldosterone-synthase overexpression in heart: a tool to explore Aldosterone's effects.
    Molecular and cellular endocrinology, 2004
    Co-Authors: C Heymes, A Garnier, S Fuchs, J K Bendall, J Nehme, M L Ambroisine, E Robidel, B Swynghedauw, P Milliez, C Delcayre
    Abstract:

    Clinical observations indicate that elevated Aldosterone impairs cardiovascular function. The mechanisms, however, are not totally understood although total and cardiovascular mortality are decreased by Aldosterone antagonists. Experimentally, increased plasma Aldosterone induces pericoronary inflammation and cardiac fibrosis. Our laboratory has discovered that Aldosterone is synthesized in the rat heart, and has demonstrated that this cardiac Aldosterone is involved in post-infarction cardiac remodeling. In man, activated cardiac Aldosterone production has been described in patients with heart failure. In transgenic mice that overexpress Aldosterone-synthase in the heart, we observe a normal cardiac function but a major coronary dysfunction, more pronounced in males. These observations converge to a potential physiological and pathological relevance of this system. Beneficial effects of anti-Aldosterone treatment in heart failure may thus be secondary in part to blockade of cardiac Aldosterone action.

Van Der Schueren Thierry - One of the best experts on this subject based on the ideXlab platform.

  • Gestion de l’hyperkaliémie lors d’un traitement par inhibiteur du système réinine-angiotensine-aldostérone
    2020
    Co-Authors: Krzesinski Jean-marie, Van Der Schueren Thierry
    Abstract:

    L’hyperkaliémie est fréquente chez le patient avec insuffisance rénale chronique (IRC), diabète et/ou décompensation cardiaque (DC) et se majore lors de la prise d’inhibiteurs du système rénineangiotensine-aldostérone. À côté de la diététique, l’usage de chélateurs intestinaux du potassium est fréquent mais souvent mal toléré. Depuis peu, un nouveau chélateur du potassium apparait prometteur.Hyperkalemia is common in patients with chronic renal failure (CKD), diabetes and/or cardiac decompensation (CD) and increases when taking inhibitors of the renin-angiotensin-Aldosterone system. Besides dietetics, the use of intestinal potassium chelators is frequent but often poorly tolerated. Recently, a new potassium chelator appears to be promising.Peer reviewe

  • Gestion de l’hyperkaliémie lors d’un traitement par inhibiteur du système réinine-angiotensine-aldostérone
    Société Scientifique de Médecine Générale, 2020
    Co-Authors: Krzesinski Jean-marie, Van Der Schueren Thierry
    Abstract:

    peer reviewedaudience: professional, studentL’hyperkaliémie est fréquente chez le patient avec insuffisance rénale chronique (IRC), diabète et/ou décompensation cardiaque (DC) et se majore lors de la prise d’inhibiteurs du système rénineangiotensine-aldostérone. À côté de la diététique, l’usage de chélateurs intestinaux du potassium est fréquent mais souvent mal toléré. Depuis peu, un nouveau chélateur du potassium apparait prometteur.Hyperkalemia is common in patients with chronic renal failure (CKD), diabetes and/or cardiac decompensation (CD) and increases when taking inhibitors of the renin-angiotensin-Aldosterone system. Besides dietetics, the use of intestinal potassium chelators is frequent but often poorly tolerated. Recently, a new potassium chelator appears to be promising